跳转至内容
Merck
CN

SML4229

BI 2536

≥98% (HPLC), powder, Plk1 inhibitor

别名:

4-[[(7R)-8-Cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)benzamide, (R)-4-[(8-Cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl)amino]-3-methoxy-N-(1-methyl-4-piperidinyl)benzamide, BI-2536, BI-2536,Polo-like Kinase Inhibitor IV

登录 查看组织和合同定价。

选择规格

变更视图

关于此项目

经验公式(希尔记法):
C28H39N7O3
化学文摘社编号:
分子量:
521.65
MDL number:
NACRES:
NA.21
Assay:
≥98% (HPLC)
Form:
powder
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


Quality Segment

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

-10 to -25°C

SMILES string

O=C(NC1CCN(C)CC1)C2=CC=C(NC(N=C3N(C4CCCC4)[C@@H]5CC)=NC=C3N(C)C5=O)C(OC)=C2

Application

BI 2536 may be used in targeting polo-like kinase 1 (PLK1) in cancer therapy; and studying its role in neuroblastoma.

Biochem/physiol Actions

BI 2536 is an ATP-competitive, potent and selective polo-like kinase 1 (Plk1) inhibitor (Plk1/2/3 IC50 = 0.83/3.5/9.0 nM; [ATP] = 7.5 µM) that induces mitotic arrest and apoptosis in human cancer cultures (EC50 <100 nM among 32 different cancer lines) and suppresses human cancer xenografts tumor growth in nude mice in vivo (50-60 mg/kg i.v. twice weekly on two consecutive days; HCT116 and NCI-H460).


存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库